Umbilical Cord-Derived Stem Cells in Treating Patients with High Risk or Steroid Refractory Acute Graft Versus Host Disease
Trial Status: closed to accrual
This phase I trial studies the best dose and side effects of umbilical cord-derived stem cells in treating patients with acute graft versus host disease that is high risk or that is not responding to treatment with steroids (steroid refractory). MSCTC-0010 is made of Wharton's Jelly stem cells found in the gelatinous insides of an umbilical cord that has been donated. These stem cells work with the immune system in the human body, and may help to reduce tissue inflammation and help with tissue repair.